Skip to content
Adrienne Monson – Lifestyle
Author:
Trevi Therapeutics, Inc.
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
April 20, 2026
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
April 16, 2026
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
April 16, 2026
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
March 17, 2026
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
March 9, 2026
←
Previous Page
1
2